中草药治疗头痛:高质量随机对照试验的系统评价与荟萃分析
荟萃分析显示,中草药单药在减少头痛频率、头痛天数、头痛持续时间、头痛强度及镇痛药消耗方面优于安慰剂,在多数结局上优于西药常规治疗,且不良事件较少,但结果因临床异质性需谨慎解读。
要点
- 中草药单药在减少头痛频率、天数、持续时间、强度及镇痛药消耗上优于安慰剂。
- 与西药常规治疗相比,中草药单药在多数结局上更优,但未显著缩短头痛持续时间。
- 中草药联合西药可提高临床有效率,且不良事件少于对照。
核心结论
- 研究结果在一定程度上支持中草药用于头痛患者,但因临床异质性应谨慎对待。
研究设计与样本
- 系统评价与荟萃分析,检索六个电子数据库至2018年1月,纳入符合Cochrane偏倚风险工具7个域中至少4个域要求的随机对照试验。
主要发现
- 中草药单药对比安慰剂:减少头痛频率SMD -0.48(95%CI -0.76, -0.20),p<0.01;减少头痛天数SMD -0.29(95%CI -0.45, -0.13),p<0.01;缩短头痛持续时间SMD -0.58(95%CI -0.81, -0.36),p<0.01;降低头痛强度SMD -0.42(95%CI -0.62, -0.23),p<0.01;减少镇痛药消耗SMD -0.36(95%CI -0.52, -0.21),p<0.01;提高临床有效率p<0.01。
- 中草药单药对比西药常规治疗:减少头痛频率SMD -0.57(95%CI -0.84, -0.29),p<0.01;减少头痛天数p<0.01;减少镇痛药消耗SMD -1.63(95%CI -1.98, -1.28),p<0.01;降低头痛强度SMD -0.81(95%CI -1.06, -0.57),p<0.01;提高临床有效率RR 1.24(95%CI 1.18, 1.31),p<0.01;但在缩短头痛持续时间上无显著差异(p>0.05)。
- 中草药辅助治疗对比单用西药常规治疗:提高临床有效率RR 1.15(95%CI 1.09, 1.22),p<0.01。
- 中草药的不良事件少于对照。
关键数值与推荐
- 纳入的随机对照试验需满足Cochrane偏倚风险工具7个域中至少4个域的要求。
临床怎么用
- 中草药单药或联合西药可用于头痛患者以改善头痛相关结局,但需结合临床异质性谨慎决策。
局限性
- 所有纳入试验均在亚洲进行,结果外推需谨慎。
- 存在临床异质性,作者提示应谨慎对待结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chinese herbal medicines (CHMs) are widely used to relieve headache in Asia. However, it is uncertain whether there is robust evidence on the effects of CHMs for headache. PURPOSE: To assess the effectiveness and safety of CHMs for headache using systematic review of high-quality randomized controlled trials (RCTs). METHODS: Electronic search was conducted on six databases from inception to January 2018. We included the RCTs that met the requirement of at least 4 out of the 7 domains according to the Cochrane risk of bias tool. RESULTS: Thirty RCTs with 3447 subjects were ultimately included for analysis and all trials were conducted in Asia. Meta-analysis showed that CHMs monotherapy were superior to placebo in reducing headache frequency [SMD -0.48 (95% CI -0.76, -0.20); p < 0.01], headache days [SMD -0.29 (95% CI -0.45, -0.13); p < 0.01], headache duration[SMD -0.58 (95% CI -0.81, -0.36); p < 0.01], headache intensity [SMD -0.42 (95% CI -0.62, -0.23); p < 0.01] and analgesic consumption [SMD -0.36 (95% CI -0.52, -0.21); p < 0.01] and improving clinical efficacy rate (p < 0.01). Similarly, CHMs monotherapy were superior to western conventional medicines (WCMs) in headache frequency [SMD -0.57 (95% CI -0.84, -0.29); p < 0.01], headache days (p < 0.01), analgesic consumption [SMD -1.63 (95% CI -1.98, -1.28); p < 0.01], headache intensity [SMD -0.81 (95% CI -1.06, -0.57); p < 0.01], and clinical efficacy rate [RR 1.24 (95% CI 1.18, 1.31); p < 0.01], except reducing headache duration (p > 0.05). CHMs adjunct therapy can improve clinical efficacy rate compared with WCMs alone [RR 1.15 (95% CI 1.09, 1.22); p < 0.01]. Meanwhile, CHMs had fewer adverse events than that of controls. CONCLUSION: The findings supported, at least to an extent, the use of CHM for headache patients; however, we should treat the results cautiously because the clinical heterogeneity.
引用
- Shi YH, Wang Y, Fu H, et al. Chinese herbal medicine for headache: A systematic review and meta-analysis of high-quality randomized controlled trials. Phytomedicine. 2018. PMID: 30807986. doi:10.1016/j.phymed.2018.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。